Assessment of the effects of telmisalthan and olmesartan on blood pressure, proteinuria, inflammation and oxidative stress in chronic kidney disease patients.

Trial Profile

Assessment of the effects of telmisalthan and olmesartan on blood pressure, proteinuria, inflammation and oxidative stress in chronic kidney disease patients.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2009

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Telmisartan (Primary)
  • Indications Cardiovascular disorders; Essential hypertension; Hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top